Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Delirium, an acute change in mental status, is a serious medical complication among hospitalized patients. Syndrome of delirium involves agitation, sleep disturbance, affective disorders and cognitive disruptions.

One vulnerable period for developing delirium is in the postoperative days. Postoperative delirium often initiates a cascade of adverse consequences including an increase in length of stay and hospital costs, and greater mortality. The investigators have observed that the incidence of postoperative delirium in patients after renal transplantation is about 20-30% in our hospital.

Several studies have revealed that dexmedetomidine, as a widely used sedative during anesthesia, can decrease the incidence of postoperative delirium after cardiac surgery. The investigators aim to examine whether administration of dexmedetomidine can reduce postoperative delirium after living donor renal transplantation in adult patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Dexmedetomidine on Postoperative Renal Function Recovery After Kidney Transplantation in Adult Patients

NCT02874378

Renal Failure

UNKNOWN NA

Dexmedetomidine and Delirium in Patients After Cardiac Surgery

NCT02267538

Delirium C.Surgical Procedure; Cardiac Postoperative Complications

COMPLETED PHASE4

Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction

NCT02923128

Postoperative Cognitive Dysfunction Postoperative Delirium

COMPLETED PHASE4

Dexmedetomidine Effect on Delirium of Elderly Patients

NCT06111300

Delirium in Old Age

NOT_YET_RECRUITING PHASE4

Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients

NCT01851005

Elderly Patients Anesthesia Emergence From Anesthesia +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Delirium After Living Donor Renal Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine

Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.

Group Type EXPERIMENTAL

Dexmedetomidine

Intervention Type DRUG

Saline

Saline ivpump 0.2ug/kg/h during living donor renal transplantation.

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

Intervention Type DRUG

Saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 17 and \< 60 years;
* American Society of Anesthesiology (ASA) I-III;
* admitted for living donor renal transplantation.

Exclusion Criteria

* Patients with a history of drug abuse;
* preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, inability to communicate in the preoperative period (coma, profound dementia, or language barrier).

Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No